Stocks and InvestingStocks and Investing
Fri, January 13, 2023
Thu, January 12, 2023
Wed, January 11, 2023

Judah Frommer Maintained (STOK) at Buy with Decreased Target to $32 on, Jan 11th, 2023


Published on 2024-10-28 00:52:34 - WOPRAI, Judah Frommer
  Print publication without navigation


Judah Frommer of Credit Suisse, Maintained "Stoke Therapeutics, Inc." (STOK) at Buy with Decreased Target from $38 to $32 on, Jan 11th, 2023.

Judah has made no other calls on STOK in the last 4 months.



There are 2 other peers that have a rating on STOK. Out of the 2 peers that are also analyzing STOK, 0 agree with Judah's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Judah


  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $35 on, Monday, December 5th, 2022
  • Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $25 on, Monday, November 14th, 2022